SeQuent–Viyash merger gets NCLT approval

Hyderabad: SeQuent Scientific Ltd., a leading global animal health company, and Hyderabad-based Viyash Lifesciences Pvt. Ltd., an integrated pharmaceutical manufacturer, have received approval from the National Company Law Tribunal (NCLT) for their proposed merger, paving the way for the creation of India’s largest animal health enterprise.

The NCLT’s clearance marks a major milestone for both companies, setting the stage for a combined entity with the scale, capabilities and financial strength to accelerate its global ambitions. Together, the companies reported aggregate revenues of Rs16.5 billion and an EBITDA of Rs3.2 billion for the first half of FY26, supported by a healthy net debt-to-EBITDA ratio of 0.7x. In Q2 FY25–26 alone, the merged operations delivered 16 per cent growth in sales and a 76 per cent surge in EBITDA, reflecting strong operational and strategic synergies.

The newly combined organisation is positioned to leverage two major long-term opportunities in the global animal health industry: Rapidly expanding companion animal (pet) health segment: With rising pet ownership and growing demand for advanced treatments in dermatology, orthopaedics, diabetes, cardiology and oncology, the segment mirrors high-growth trends in human healthcare; Accelerating shift toward generic animal health products: With genericisation still lagging behind human pharmaceuticals, the companies see significant opportunity to apply their strengths in APIs, formulations and advanced R&D to expand their product pipeline and scale their fast-growing CDMO business.

The merger is expected to enhance the group’s organic growth engine while strengthening its financial resilience and providing additional management depth to drive future inorganic expansion.